Scholarlink

<p>Alzheimer’s disease (AD) is the most common cause of dementia, and its overall incidence is rising as the proportion of older individuals in the population increases. Traditional diagnostic methods, such as lumbar puncture and neuroimaging, are costly and invasive, driving the search for blood-based biomarkers (BBB) for early diagnosis. The quantification of these biomarkers requires ultrasensitive techniques, such as the single-molecule array (SIMOA) platform. This systematic review synthesizes the available evidence on the biomarkers β-amyloid (Aβ42, Aβ40, and their ratio), tau protein (t-Tau, p-Tau181, p-Tau231, p-Tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in studies analyzing their blood concentrations using SIMOA, regardless of the platform model (SR-X, HD-1, HD-X). Findings support the potential of plasma biomarkers as an alternative or complement to invasive methods, although further validation is required before clinical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma Biomarkers for Alzheimer’s Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • María de los Ángeles Fernández-Ceballos,
  • José M. Prieto-González,
  • Roberto Carlos Agís-Balboa

摘要

Alzheimer’s disease (AD) is the most common cause of dementia, and its overall incidence is rising as the proportion of older individuals in the population increases. Traditional diagnostic methods, such as lumbar puncture and neuroimaging, are costly and invasive, driving the search for blood-based biomarkers (BBB) for early diagnosis. The quantification of these biomarkers requires ultrasensitive techniques, such as the single-molecule array (SIMOA) platform. This systematic review synthesizes the available evidence on the biomarkers β-amyloid (Aβ42, Aβ40, and their ratio), tau protein (t-Tau, p-Tau181, p-Tau231, p-Tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in studies analyzing their blood concentrations using SIMOA, regardless of the platform model (SR-X, HD-1, HD-X). Findings support the potential of plasma biomarkers as an alternative or complement to invasive methods, although further validation is required before clinical implementation.